DIAGNOSIS AND MANAGEMENT OF COMBINED COMPLICATIONS OF CHEMOTHERAPY IN NON-HODGKIN LYMPHOMA PATIENT IN GENERAL PRACTICE

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


The article presents the observation of patients with toxic cardiomyopathy and oropharyngeal candidiasis after chemotherapy with anthracyclines, particularly with «doxorubicin

Full Text

Restricted Access

About the authors

G V Kiseleva

North-Western State Medical University named after I. I. Mechnikov

Email: kongruentn@yandex.ru

F Islam

North-Western State Medical University named after I. I. Mechnikov

References

  1. Armitage J.O. Treatment of non-Hodgkin‘s lymphoma // N. Engl. J. Med. - 1993. - Vol. 328. - № 14. - P. 1023-1030.
  2. Di Marco A., Cassinelli G., Arcamone F. The discovery of daunorubicin // Cancer. Treat. Rep. - 1981. - Vol. 4. - № 65. - Р. 3-8.
  3. Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity // Cancer. - 1973. - Vol. 32. - № 2. - Р. 302-314.
  4. Von Hoff D.D., Layard M.W., Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure // Ann. Intern. Med. - 1979. - Vol. 91. - № 5. - Р. 710.
  5. Alexander J., Dainiak N., Berger H. J., et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography // N. Engl. J. Med. - 1979. - Vol. 300. - № 6. - Р. 278-283.
  6. Buzdar A. U., Marcus C., Smith T.L., et al. Early and delayed clinical cardiotoxicity of doxorubicin // Cancer. - 1985. - Vol. 55. - № 12. - P. 2761-2765.
  7. Ewer S.M., Ewer M.S. Cardiotoxicity profile of trastuzumab // Drug Saf. - 2008. - Vol. 31. - № 6. - Р. 459-467.
  8. Oliveira P.J., Bjork J.A., Santos M. S. et al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity // Toxicol. Appl. Pharmacol. - 2004. - Vol. 200. - № 2. - P. 159-168.
  9. Spallarossa P., Garibaldi S., Altieri P. et al. Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro // J. Mol. Cell. Cardiol. - 2004. - Vol. 37. - № 4. - P. 837-846.
  10. Cardinale D., Colombo A., Lamantia G. et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy // J. Am. Coll. Cardiol. -2010. - Vol. 55. - № 3. - P. 213-220.
  11. Yoon G.J., Telli M.L., Kao D.P. et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? // J. Am. Coll. Cardiol. -2010. - Vol. 56. - № 20. - P. 1644-1650.
  12. Супрончук Н.В., Дмитриев В.Л., Важенин A. B., Гладков О. А. Роль доксорубицина в патогенезе ремоделирования левого желудочка и сердечной недостаточности у больных раком молочной железы // Сибирский онкологический журнал. - 2007. - № 3-4. - С. 26-31.
  13. Yoo S.S., Lee W.H., Ha J., Choi S., Kim H.J., Kim T.H., Lee O.J. Prevalence of esophageal disorders in the subjects examined for health screening // Korean J. Gastroenterol. - 2007. - Vol. 50. - № 5. - Р. - 306-312.
  14. Pappas P.G., Rex J.H., Sobel J.D., Filler S.G., Dismukes W.E., Walsh T.J., Edwards J.E. Practical guyde of candidiasis treatment // Clinical Infection Diseases. - 2004. - Vol. 38. - P. 161-189.
  15. Mulcahy N. New standard of care for oral mucositis // Medscape Medical News. - October 30. - 2012. - http://www.medscape.com/viewarticle/773567. - Последнее посещение сайта 11.04.2015 г.

Statistics

Views

Abstract - 500

PDF (Russian) - 339

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


Copyright (c) 2015 Kiseleva G.V., Islam F.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies